CIM
ALDR

Contravisory Investment Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Contravisory Investment Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-16
Closed – – 494
2017
Q4 		$0 Hold
16
– – ﹤0.01% 549
2017
Q3 		$0 Buy
+16
New +$167 ﹤0.01% 516

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Contravisory Investment Management's ALDR Position: Q1 2018 in Review

Contravisory Investment Management sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 16 shares.

Contravisory Investment Management first reported a position in ALDR in Q3 2017 and held it in 2 quarters. The position peaked at $0 in Q4 2017. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

  • Contravisory Investment Management reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Contravisory Investment Management sold 16 Alder Biopharmaceuticals shares in Q1 2018.
  • Contravisory Investment Management first reported a position in Alder Biopharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Contravisory Investment Management's Alder Biopharmaceuticals position peaked at $0 in Q4 2017.
  • 135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Contravisory Investment Management's 13F filing for Q1 2018, filed 9 Apr 2018.